• In early May 2026, AbbVie reported that shareholders voted against a proposal to require an independent board chair while the company highlighted extensive new real‑world and long‑term data for its key immunology drugs SKYRIZI and RINVOQ in inflammatory bowel disease.
• The combination of fresh efficacy and quality‑of‑life data for these therapies and continued conference outreach underscores how central immunology remains to AbbVie’s business profile.
• We’ll now examine how AbbVie’s latest immunology data presentations could influence its investment narrative around future growth drivers and risks.

AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

AbbVie Investment Narrative Recap

To own AbbVie, you need to believe its immunology engine, led by SKYRIZI and RINVOQ, can offset life cycle and pricing pressures while supporting dividends and debt. The latest real world IBD data strengthen the profile of these therapies, but do not materially change the near term catalyst of execution in immunology or the ongoing risk from drug price reforms and concentrated product exposure.

The most relevant update here is AbbVie’s 18 abstract package at Digestive Disease Week 2026, including 52 week ASPIRE CD follow up for SKYRIZI and real world RINVOQ outcomes. These data speak directly to persistence on therapy, quality of life and healthcare utilization, which tie into the core growth driver narrative for immunology at a time when regulators and payers are increasingly focused on value and cost.

Yet against this backdrop, investors still need to consider the growing policy and pricing scrutiny that could...

AbbVie’s narrative projects $77.7 billion revenue and $22.4 billion earnings by 2029. This requires 8.3% yearly revenue growth and an earnings increase of about $18.2 billion from $4.2 billion today.

Uncover how AbbVie's forecasts yield a $249.43 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Four members of the Simply Wall St Community see AbbVie’s fair value between US$249 and US$419 per share, showing wide dispersion in expectations. Set against AbbVie’s dependence on a concentrated immunology portfolio, this spread underlines why you may want to compare several viewpoints before deciding how resilient you think its future performance could be.

Explore 4 other fair value estimates on AbbVie - why the stock might be worth as much as 99% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your AbbVie research is our analysis highlighting 3 key rewards and 5 important warning signs that could impact your investment decision.
• Our free AbbVie research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AbbVie's overall financial health at a glance.

Contemplating Other Strategies?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 47 companies with promising cash flow potential yet trading below their fair value.
• Capitalize on the AI infrastructure supercycle with our selection of the 40 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.